Disability benefits including PIP, DLA and Attendance Allowance are not currently means-tested.
The Department for Work and Pensions has confirmed that no assessment has been made into the potential costs involved of means-testing Personal Independence Payment , following Secretary of State Mel Stride’s comments in Parliament last week.
In a written response on November 8, DWP Minister for Disabled People, Tom Pursglove, said: “Personal Independence Payment, as for all the extra costs disability benefits, is not means tested. No assessment has been made of the administrative costs of introducing a means test.” The Labour MP added: “The Prime Minister tells us that we do not need a general election because the 2019 manifesto gives him and the Conservative party a mandate.
Top Money Stories Today Mr Stride did not rule out making disability benefits means-tested, instead he opted not to offer a direct response.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Lewis Capaldi posts throwback photo from school days 'bragging' about attendanceThe Forget Me singer attended primary and secondary school in West Lothian, and he posted a tweet 'bragging' about his 100 per cent attendance record in his younger days.
Read more »
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisBackground To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing–remitting multiple sclerosis switching from fingolimod. Methods Using data from MSBase registry, this multicentre cohort study included subjects who had used fingolimod for ≥6 months and then switched to ocrelizumab, cladribine or natalizumab within 3 months after fingolimod discontinuation. We analysed relapse and disability outcomes after balancing covariates using an inverse-probability-treatment-weighting method. Propensity scores for the three treatments were obtained using multinomial-logistic regression. Due to the smaller number of cladribine users, comparisons of disability outcomes were limited to natalizumab and ocrelizumab. Results Overall, 1045 patients switched to ocrelizumab (n=445), cladribine (n=76) or natalizumab (n=524) after fingolimod. The annualised relapse rate (ARR) for ocrelizumab was 0.07, natalizumab 0.11 and cladribine 0.25. Compared with natalizumab, the ARR ratio (95% confidence interval [CI]) was 0.67 (0.47 to 0.96) for ocrelizumab and 2.31 (1.30 to 4.10) for cladribine; the hazard ratio (95% CI) for time to first relapse was 0.57 (0.40 to 0.83) for ocrelizumab and 1.18 (0.47 to 2.93) for cladribine. Ocrelizumab users had an 89% lower discontinuation rate (95% CI, 0.07 to 0.20) than natalizumab, but also a 51% lower probability of confirmed disability improvement (95% CI, 0.32 to 0.73). There was no difference in disability accumulation. Conclusion After fingolimod cessation, ocrelizumab and natalizumab were more effective in reducing relapses than cladribine. Due to the low ARRs in all three treatment groups, additional observation time is required to determine if statistical difference in ARRs results in long-term disability differences. Data are available upon reasonable request. In principle, patient-level data sharing is possible. However, permission from each contributing data controller is requi
Read more »
COP27 latest: Boris Johnson's dig at Liz Truss - as world warned it is 'on highway to climate hell'Rishi Sunak is giving a speech in Sharm el-Sheikh, Egypt, after U-turning on his attendance; Boris Johnson is also in town but insists he is just a 'foot soldier'; the taboo issue of richer countries compensating poor countries is also on the agenda.
Read more »
COP27 latest: Sunak commits billions to climate fund - as world warned it is 'on highway to hell'Rishi Sunak has given a speech in Sharm el-Sheikh, Egypt, after U-turning on his attendance; Boris Johnson is also in town but insists he is just a 'foot soldier'; the taboo issue of richer countries compensating poor countries is also on the agenda.
Read more »
US midterm elections: Who won, who lost and what it meansVotes are still being counted across the US but it's clear that there's already one big winner.
Read more »